

340B Practice Fact Sheet

BMS has announced 340B practice updates that will apply to all 340B covered entity types effective November 1, 2023. BMS remains committed to working with covered entities to protect the integrity of the 340B program and to help ensure that uninsured and low-income patients can access the medications they need at the 340B price. BMS will continue to apply its practice as circumstances require to fulfill applicable legal obligations and support practice requirements.

Questions regarding these 340B practice updates may be submitted to BMS340B@bms.com.

Contract Pharmacy Practice

BMS will recognize up to **three** designated 340B contract pharmacy locations for each 340B covered entity that does not have its own entity-owned pharmacy: one for certain of our covered outpatient drugs (non-IMiDs), a second for our immunomodulatory drugs (IMiDs) (Revlimid[®], Pomalyst[®], and Thalomid[®]), and a third for Camzyos[®]. BMS will continue to offer 340B prices on drugs sold to covered entities and delivered to their entity-owned pharmacies in compliance with applicable law. To ensure transparency and program integrity at designated contract pharmacies, BMS expects that all dispensing to 340B-eligible patients will occur at the properly designated contract pharmacy location(s), and that 340B drugs will be shipped directly to that location either by BMS or an authorized distributor.

Non-IMiDs. BMS will permit each covered entity that lacks its own entity-owned pharmacy to select and utilize a single designated contract pharmacy location for non-IMiD products (excluding Camzyos[®]). The non-IMiD contract pharmacy location selected by the covered entity need not be the same pharmacy as the IMiD or Camzyos[®] contract pharmacy location, although it may be.

IMiDs. 340B covered entities that are not already part of the IMiD limited distribution network will have the option to access the IMiDs at 340B prices through one in-network IMiD-designated specialty contract dispensing pharmacy location per applicable covered entity. This update does not amend or expand the IMiD limited distribution network of pharmacies and will not affect access to the IMiDs for any patient. Patients receiving IMiDs will still be able to receive their medications from the same dispensaries. Entities that choose to access IMiDs at 340B prices at an IMiD-designated specialty contract pharmacy location will submit claim information to BMS directly. Only one 340B purchase may occur on a single eligible IMiD prescription. Multiple 340B requests on a single prescription will not be allowed.

Camzyos[®]. 340B covered entities that are not already part of the Camzyos[®] limited distribution network will have the option to access Camzyos[®] at 340B prices through one in-network Camzyos[®]-designated specialty contract dispensing pharmacy location per applicable covered entity.